Serena Macauley, APRN
Psychiatric/Mental Health · Lincoln, NENPI 1205065679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 505 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,827, 2.1 times the $879 reported in 2021. Among psychiatric/mental health clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 505 payments — averaging $14.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$682
- Supernus Pharmaceuticals, Inc.$553
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$520
- Teva Pharmaceuticals USA, Inc.$394
- plus $2K from 26 others
What the payments were for
- Food & beverage$7,09299%
- Education$1031%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,194 in reported general payments places this provider in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $109,747 |
| VraylarCariprazine Hcl | 71 | $106,039 |
| AuvelityDextromethorphan Hbr/Bupropion | 87 | $91,763 |
| RexultiBrexpiprazole | 56 | $90,611 |
| FanaptIloperidone | 20 | $71,176 |
| CaplytaLumateperone Tosylate | 29 | $47,252 |
| VyvanseLisdexamfetamine Dimesylate | 64 | $28,129 |
| Clozapine OdtClozapine | 39 | $27,255 |
| FetzimaLevomilnacipran Hcl | 43 | $21,758 |
| BelsomraSuvorexant | 41 | $21,180 |
| Adzenys Xr-OdtAmphetamine | 15 | $15,077 |
| TrintellixVortioxetine Hydrobromide | 25 | $11,554 |
| HorizantGabapentin Enacarbil | 16 | $10,378 |
| Divalproex Sodium | 27 | $9,477 |
| Aripiprazole | 74 | $8,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,452 | $127,798114 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $105 | $109,74713 claims |
| Axsome Therapeutics, Inc.Auvelity | $210 | $91,76387 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $682 | $90,61156 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $59 | $71,17620 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix, Adderall | $145 | $47,561102 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $520 | $47,25229 claims |
| MerckBelsomra | $15 | $21,18041 claims |
| Neos Therapeutics, LPAdzenys Xr-Odt | $85 | $15,07715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Lincoln
- Helen TrotterLincoln$10K
- Marcia CarlsonLincoln$9K
- Trisha JobmanLincoln$9K
- Cory RabeLincoln$9K
- Kelley HanauLincoln$8K
- Tami OrtonLincoln$8K
- Michelle LemonLincoln$7K
- Sabrina HellbuschLincoln$7K
- Rebecca OlanderLincoln$7K
- Lisa YoungLincoln$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.